Printer Friendly

TELIOS ANNOUNCES SECOND QUARTER 1992 RESULTS

 TELIOS ANNOUNCES SECOND QUARTER 1992 RESULTS
 SAN DIEGO, Aug. 5 /PRNewswire/ -- Telios Pharmaceuticals Inc.


("Telios" or the "Company") (NASDAQ-NMS: TLIO) announced today financial results for its second quarter and the six-month period ending June 30, 1992. Revenues for the quarter were $1,402,000, a decrease from $2,678,000 for the same period last year. The Company incurred a net loss of $5,424,000 or $.28 per share, compared to a net loss of $490,000 or $.03 per share for the same period in 1991. Year-to-date revenues and net loss were $1,929,000 and $9,732,000, respectively, for 1992, compared to $3,465,000 and $2,111,000, respectively, for the same period of 1991. Year-to-date net loss per share was $.53 for 1992 compared to $.13 for the same period in 1991. The increased loss for both periods was primarily the result of increased clinical, research and development activities and lower revenues under collaborative research and development agreements which typically generate revenues that fluctuate significantly from quarter to quarter or from year to year.
 Telios is developing a new class of therapeutic products based upon research into the role of the extracellular matrix. The Company is applying its proprietary technology to develop products for the treatment of severe and chronic dermal wounds, ophthalmic wounds, fibrotic disease, cardiovascular disease and osteoporosis. The Company currently is in clinical trials with two novel peptide-based products, Telio-Derm(TM), a treatment designed to accelerate healing of severe and chronic dermal wounds, and OcuNex(TM), an ophthalmic wound healing product.
 The common stock of Telios is traded on the NASDAQ National Market System under the symbol TLIO.
 -0- 8/5/92
 /CONTACT: Audrey D. Keane (press), director of Corporate Development, or David Duncan Jr., VP-finance, or Richard A. Kaufman, VP, secretary and general counsel (investors), 619-622-2615, all of Telios Pharmaceuticals/
 (TLIO) CO: Telios Pharmaceuticals Inc. ST: California IN: MTC SU: ERN


AL-JL -- SD007 -- 7352 08/05/92 20:26 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 5, 1992
Words:330
Previous Article:SO LONG SOYBEAN PIZZA: KID CUISINE OFFERS NUTRITIONAL MEALS FOR TODAY'S KIDS
Next Article:LOCAL 250 AND KAISER-PERMANENTE BEGIN BARGAINING NEW CONTRACT; 13,000 WORKERS IN 30 HEALTH CARE FACILITIES
Topics:


Related Articles
TELIOS PHARMACEUTICALS INC. SELLS 2.5 MILLION SHARES OF COMMON STOCK IN INITIAL PUBLIC OFFERING
TELIOS ANNOUNCES FIRST QUARTER 1992 RESULTS
LIFE TECHNOLOGIES INC. ACQUIRES ASSETS OF RESEARCH PRODUCTS DIVISION OF TELIOS PHARMACEUTICALS INC.
TELIOS ANNOUNCES THIRD QUARTER 1992 RESULTS
LEADING RESEARCHERS REPORT THAT TP-9201 PREVENTS BLOOD CLOTTING WITHOUT INCREASING BLEEDING TIME
TELIOS PHARMACEUTICALS SIGNS AN AGREEMENT WITH LILLY TO DEVELOP NOVEL OSTEOPOROSIS THERAPEUTICS
TELIOS SUBMITS PMA FOR TELIO-DERM(R) WOUND HEALING AGENT
TELIOS ANNOUNCES FIRST QUARTER 1993 RESULTS
TELIOS ANNOUNCES SECOND QUARTER 1993 RESULTS
Integra LifeSciences Receives Nearly $600,000 in Grants

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters